Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG ("FGen"), a Swiss company specializing in strain development and optimization. FGen has developed an ultra-high-throughput (uHT) screening platform built on nanoliter reactor technology. Ginkgo believes that FGen's technology will significantly enhance Ginkgo's cell screening capabilities and enable Ginkgo to explore wider expanses of genetic opportunity space, increasing the likelihood of finding enzymes, pathways, and strains or cell lines that perform to diverse product specifications. Ginkgo and FGen plan to close the transaction promptly. Post-closing, Ginkgo expects that the integration of FGen's platform can greatly increase the capacity of Ginkgo's Design-Build-Test-Learn strain development engine, a foundation of Ginkgo's technology stack. By adding FGen's uHT screening platform to its existing HT screening systems, Ginkgo seeks to be able to routinely analyze the performance of millions of genetic prototypes in pooled format, upgrading the quality of candidate hits that feed into downstream workflows for strain characterization and validation. FGen's platform is extremely flexible across organisms, pathways, and target products. The platform can be deployed to screen for both intracellular and secreted target products as well as both small molecules and proteins. It can also accommodate diverse organisms including bacteria, yeast, filamentous species, and mammalian cells. "Ginkgo is committed to investing in creating the premier cell programming platform by integrating best-in-class tools from around the world and deploying them broadly across our programs," said Barry Canton, Ginkgo's co-founder and Chief Technology Officer. "We have worked with the FGen team for several years and believe their technology and world-class scientists will allow us to further improve our ability to explore an exponentially wider design space and deliver more value for our customers." "Our team has spent the last decade building one of the most advanced screening platforms in the world in the hopes of enabling breakthrough discoveries and products across industries," said Andreas Meyer, Chief Executive Officer of FGen. "We are excited to be welcomed onto the Ginkgo platform where we can deploy this technology much more broadly and better support customers and their world-changing work." Under the terms of the transaction, FGen will receive upfront payment and additional contingent consideration related to, among other things, the successful integration and deployment of the FGen technology across Ginkgo programs.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!